Drug development project for peptides to treat Wilsons' Disease. • Solid-phase peptide synthesis (SPPS) using Fmoc-based strategy • Late-stage modifications in solution, such as cyclization of linear peptides • Purification by medium-pressure liquid chromatography (MPLC) • Liquid chromatography-mass spectrometry (LCMS) analysis • 1H, 13C and 19F NMR spectroscopy • UV-Vis titration assays for binding affinity and metal selectivity determination • Cell-based assays for determining the efficacy and safety of the peptides • siRNA knockdown in vitro

• Management of REDCap (up/downloading data, implementing surveys, design of data collection tools) • Data cleaning and (statistical) data analysis with R, writing of scientific reports/publications • Organization of the entire study in compliance with ethics protocol and GCP guidelines • Management of the study administration in compliance with ethics protocol and GCP guidelines • Recruitment of study participants and correspondence, planning of study visits • Correspondence and planning of study visits with schools and parents, overseeing all logistics • Creating duty rosters for study nurses and administrative staff, coordinating laboratories • Study documents (ethic protocols, participant surveys, case report and informed consent forms, log-forms, information summaries, test interpretation handouts, flyer for recruitment, SOPs) • Organizing digital study files for accessible and secure storage of all key documents according to GCP

• conducting an overview of reviews (Cochrane Chapter V.) • creating the search strategy for multiple literature databases (EMBASE, Medline etc) • screening of title/abstracts and full-texts • quality grading of included systematic reviews • data extraction of underlying primary studies (using and verifying the AI-Tool ELICIT) • writing of scientific publication

Drug development project for novel treatment options in NRAS melanoma • Cancer and healthy cell culture • 2D and 3D multicellular spheroid viability and invasion assays • Establishment of IC50 values of drug candidates in various cancer cell lines • siRNA knockdown experiments and validation • RNA/DNA isolation and bulk RNA sequencing (incl. analysis) • Flow cytometry • Immunostainings brightfield, fluorescence and confocal microscopy • Zebrafish husbandry and acute zebrafish embryo toxicity assays • Brightfield, fluorescence and confocal microscopy (incl. ImageJ macro writing) • UV/Vis titration assay to assess copper-complex formation • validation of siRNA knockdowns by western blotting and 2D/3D viability assays • Small molecule chemical binding assays • Biostatistical analysis (R studio)